An interventional study of Virtual Reality therapeutics in ICU Delirium, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Prevention
The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisting of calming natural scenes, guided meditation, and music. The study population includes adult surgical ICU patients at Cedars-Sinai who are CAM-ICU negative at enrollment and possess at least one established risk factor for delirium. Outcomes will include the incidence and duration of delirium, ICU and hospital length of stay, feasibility of the VR intervention, and the frequency of adverse events. By targeting a high-risk population with an innovative non-pharmacologic therapy, this trial aims to generate data to support integration of VR into ICU delirium prevention protocols.
Cedars-Sinai Medical Center is the lead sponsor of 441 studies on the registry; 108 are open to participants now.
Of its 62 completed or terminated interventional studies of FDA-regulated products, 47 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Virtual Reality therapeutics
Patients will receive daily VR sessions for up to 5 days in addition to regular delirium prevention measures in the ICU
Incidence of ICU Delirium
Using the CAM-ICU assessment, patients will be evaluated for the development of ICU delirium
Time frame: From enrollment in the study until ICU discharge. Assessed Day 1 in the morning and evening for the duration of the ICU admission, up to 24 months from enrollment.
Duration of ICU delirium
Number of days the patient experienced ICU delirium while admitted to the ICU
Time frame: From the time of study enrollment until the time of discharge from the ICU, up to 24 months from enrollment.
ICU-LOS
ICU length of stay
Time frame: From time admitted to the ICU until discharge from the ICU, up to 24 months from enrollment.
H-LOS
Hospital Length of stay
Time frame: From time admitted to the hospital until discharge from the hospital, up to 24 months from enrollment.
Acceptability by patients
Able to complete VR sessions as detailed in the study
Time frame: From time enrolled in the study until the patient has completed the study interventions (either on discharge from the ICU or after 5 days of interventions, whichever comes first), from Day 1 until Day 5 after enrollment.
Number of adverse events
Time frame: Adverse events related to VR, such as nausea, dizziness, seizures, will be assessed from the time of enrollment in the study up until the time of discharge from the hospital, from time of enrollment on Day 1 until Day 5 after enrollment, if applicable.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cedars-Sinai Medical Center